person · Reporting owner

STUMP DAVID C

Disclosed activity across 4 companies

Tapewire entity: 42345
SEC CIK: 0001191235

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
MACROGENICS INCMGNX · Entity 6104	Director	May 18, 2026	May 20, 2026
REGENXBIO Inc.RGNX · Entity 2211	Director	May 29, 2026	June 02, 2026
Viracta Therapeutics, Inc.SNSS · Entity 85616	Director	June 30, 2020	July 01, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MACROGENICS INC

Report date May 18, 2026 · Filed May 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	14,750	Reported balance After 2026-05-18 transaction · row 1 1 source row Row 1 · 2026-05-18 · Exercise / conversion · Acquired 3,750 · Balance 14,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-05-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-18 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	3,750	Reported balance After 2026-05-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19	Direct	22,000	Reported balance After 2026-05-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.

F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

REGENXBIO Inc.

Report date May 29, 2026 · Filed June 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,861	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 28,861 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29	Direct	46,600	Reported balance After 2026-05-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Viracta Therapeutics, Inc.

Report date June 30, 2020 · Filed July 01, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2030-06-30	Direct	60,000	Reported balance After 2020-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-30 · Grant · Acquired 60,000 · Balance 60,000 F1: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 1 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 2 1 source row Row 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11	Direct	Reported balance After 2020-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-02 · Disposition to issuer · Disposed 44,991 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.

F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F4: In connection with the Merger, these options were accelerated and canceled without payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 29, 2026 Filed Jun 2, 2026 21:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Options (Right to Buy) · Derivative	46,600	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001191235-26-000003 · primarydocument.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document
May 29, 2026 Filed Jun 2, 2026 21:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantCommon Stock	9,807	$0.00	$0.00	Disclosure SEC source: 0001191235-26-000003 · primarydocument.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,861 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document
May 19, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	22,000	$0.00 Strike: $4.52	$0.00	Disclosure SEC source: 0001191235-26-000002 · wk-form4_1779308010.xml · derivative · entry 4 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-19 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
May 19, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001191235-26-000002 · wk-form4_1779308010.xml · derivative · entry 3 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 18, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionRestricted Stock Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001191235-26-000002 · wk-form4_1779308010.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. F2 · derivative.expiration_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. Read SEC document
May 18, 2026 Filed May 20, 2026 20:13 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionCommon Stock	3,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001191235-26-000002 · wk-form4_1779308010.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:33 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Options (Right to Buy) · Derivative	39,815	$0.00 Strike: $8.85	$0.00	Disclosure SEC source: 0001562180-25-004352 · primarydocument.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer. Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:33 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantCommon Stock	7,768	$0.00	$0.00	Disclosure SEC source: 0001562180-25-004352 · primarydocument.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document
May 21, 2025 Filed May 22, 2025 20:02 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	22,000	$0.00 Strike: $1.49	$0.00	Disclosure SEC source: 0001125345-25-000081 · wk-form4_1747944148.xml · derivative · entry 4 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-05-21 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
May 21, 2025 Filed May 22, 2025 20:02 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	3,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-25-000081 · wk-form4_1747944148.xml · derivative · entry 3 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 20, 2025 Filed May 22, 2025 20:02 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionRestricted Stock Unit · Derivative	6,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-25-000081 · wk-form4_1747944148.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. F2 · derivative.expiration_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. Read SEC document
May 20, 2025 Filed May 22, 2025 20:02 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionCommon Stock	6,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001125345-25-000081 · wk-form4_1747944148.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 31, 2024 Filed Jun 4, 2024 20:39 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Options (Right to Buy) · Derivative	24,454	$0.00 Strike: $14.35	$0.00	Disclosure SEC source: 0001562180-24-004649 · primarydocument.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,454 Underlying: Common Stock · 24,454 shares Expires 2034-05-31 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document
May 31, 2024 Filed Jun 4, 2024 20:39 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantCommon Stock	4,790	$0.00	$0.00	Disclosure SEC source: 0001562180-24-004649 · primarydocument.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,286 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer. Read SEC document
May 21, 2024 Filed May 23, 2024 21:16 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	16,500	$0.00 Strike: $4.26	$0.00	Disclosure SEC source: 0001125345-24-000129 · wk-form4_1716499006.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-21 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
May 21, 2024 Filed May 23, 2024 21:16 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	6,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-24-000129 · wk-form4_1716499006.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 20, 2024 Filed May 22, 2024 20:33 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionRestricted Stock Unit · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-24-000106 · wk-form4_1716410028.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. F2 · derivative.expiration_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. Read SEC document
May 20, 2024 Filed May 22, 2024 20:33 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001125345-24-000106 · wk-form4_1716410028.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. Read SEC document
June 02, 2023 Filed Jun 6, 2023 21:12 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Options (Right to Buy) · Derivative	17,892	$0.00 Strike: $19.72	$0.00	Disclosure SEC source: 0001562180-23-004893 · primarydocument.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2033-06-02 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 2, 2023 subject to the continuous service of the optionee to the Issuer. Read SEC document
June 02, 2023 Filed Jun 6, 2023 21:12 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantCommon Stock	3,486	$0.00	$0.00	Disclosure SEC source: 0001562180-23-004893 · primarydocument.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2024 subject to the continuous service of the recipient to the Issuer. Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:54 UTC	MACROGENICS INC MGNX · Entity 6104	GrantRestricted Stock Unit · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001125345-23-000096 · wk-form4_1685739273.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:54 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	19,000	$0.00 Strike: $4.67	$0.00	Disclosure SEC source: 0001125345-23-000096 · wk-form4_1685739273.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
June 03, 2022 Filed Jun 7, 2022 20:22 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	15,324	$0.00 Strike: $22.84	$0.00	Disclosure SEC source: 0001562180-22-004880 · primarydocument.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 Underlying: Common Stock · 15,324 shares Expires 2032-06-03 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 3, 2022 while the optionee provides continuous service to the Issuer. Read SEC document
June 03, 2022 Filed Jun 7, 2022 20:22 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantCommon Stock	3,010	$0.00	$0.00	Disclosure SEC source: 0001562180-22-004880 · primarydocument.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2023 while the recipient provides continuous service to the Issuer. Read SEC document
May 19, 2022 Filed May 24, 2022 01:07 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $3.90	$0.00	Disclosure SEC source: 0001125345-22-000068 · wf-form4_165335446035323.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
June 04, 2021 Filed Jun 8, 2021 20:21 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $35.52	$0.00	Disclosure SEC source: 0001562180-21-004130 · primarydocument.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 4, 2021. Read SEC document
May 13, 2021 Filed May 18, 2021 01:30 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.88	$0.00	Disclosure SEC source: 0001125345-21-000076 · wf-form4_162130139081001.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:40 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	44,991	$0.00	$0.00	Disclosure SEC source: 0001209191-20-040371 · doc4.xml · derivative · entry 4 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,991 shares Expires not disclosed F4 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:40 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	11,377	$0.06 Strike: $17.94	$682.62	Disclosure SEC source: 0001209191-20-040371 · doc4.xml · derivative · entry 3 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F3 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F3 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:40 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerRestricted Stock Units	7,281	$18.00	$131,058.00	Disclosure SEC source: 0001209191-20-040371 · doc4.xml · nonDerivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · acquired: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:40 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerCommon Stock	13,194	$18.00	$237,492.00	Disclosure SEC source: 0001209191-20-040371 · doc4.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document
June 30, 2020 Filed Jul 1, 2020 16:39 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $0.26	$0.00	Disclosure SEC source: 0000899243-20-018122 · doc4.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document
June 12, 2020 Filed Jun 15, 2020 19:15 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	11,377	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0001209191-20-036792 · doc4.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,377 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document
June 12, 2020 Filed Jun 15, 2020 19:15 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	7,281	$0.00	$0.00	Disclosure SEC source: 0001209191-20-036792 · doc4.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2021, subject to the Reporting Person's Continuous Services (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document
May 29, 2020 Filed Jun 2, 2020 20:36 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $37.66	$0.00	Disclosure SEC source: 0001562180-20-004070 · primarydocument.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2020. Read SEC document
May 14, 2020 Filed May 15, 2020 20:38 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $24.97	$0.00	Disclosure SEC source: 0001125345-20-000093 · wf-form4_158957507216789.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-14 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document
June 28, 2019 Filed Jul 2, 2019 17:21 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $0.73	$0.00	Disclosure SEC source: 0000899243-19-018922 · doc4.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-06-28 F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 17:36 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	6,991	$0.00 Strike: $26.09	$0.00	Disclosure SEC source: 0001209191-19-037467 · doc4.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991 Underlying: Common Stock · 6,991 shares Expires 2029-06-12 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 17:36 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	4,194	$0.00	$0.00	Disclosure SEC source: 0001209191-19-037467 · doc4.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document
May 31, 2019 Filed Jun 4, 2019 20:23 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $43.02	$0.00	Disclosure SEC source: 0001562180-19-003296 · primarydocument.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2019. Read SEC document
May 16, 2019 Filed May 20, 2019 21:48 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001125345-19-000074 · wf-form4_155838889000225.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:01 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.12	$0.00	Disclosure SEC source: 0001179110-18-009425 · edgar.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-29 F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document
June 08, 2018 Filed Jun 8, 2018 18:23 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $42.81	$0.00	Disclosure SEC source: 0001209191-18-036770 · doc4.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document
June 08, 2018 Filed Jun 8, 2018 18:23 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036770 · doc4.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document
May 25, 2018 Filed May 30, 2018 20:34 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $49.45	$0.00	Disclosure SEC source: 0001562180-18-002718 · primarydocument.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-25 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 25, 2018. Read SEC document
May 17, 2018 Filed May 21, 2018 20:53 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $21.34	$0.00	Disclosure SEC source: 0001125345-18-000070 · wf-form4_152693600090813.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
June 16, 2017 Filed Jun 19, 2017 18:20 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $35.06	$0.00	Disclosure SEC source: 0001209191-17-040926 · doc4.xml · derivative · entry 2 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-16 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest each month after June 1, 2017, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document
June 16, 2017 Filed Jun 19, 2017 18:20 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040926 · doc4.xml · nonDerivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document
May 31, 2017 Filed Jun 2, 2017 17:43 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.96	$0.00	Disclosure SEC source: 0001179110-17-008462 · edgar.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: The option vests over one (1) year in equal monthly installments from the date of grant. Read SEC document
May 24, 2017 Filed May 26, 2017 21:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $18.85	$0.00	Disclosure SEC source: 0000899243-17-014568 · doc4.xml · derivative · entry 1 STUMP DAVID C · CIK 0001191235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 24, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.